51. Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice
- Author
-
Brian H. Johnston, Richard P. Harbottle, Adam Judge, Ryan Spitler, Suet Ping Wong, Ian MacLachlan, Joshua Shorenstein, Anne Dallas, Christopher H. Contag, and Heini Ilves
- Subjects
PK ,Hepatitis C virus ,lipid nanoparticles ,Biology ,medicine.disease_cause ,Small hairpin RNA ,03 medical and health sciences ,shRNA ,In vivo ,RNA interference ,Drug Discovery ,Gene expression ,medicine ,Luciferase ,sshRNA ,030304 developmental biology ,0303 health sciences ,lcsh:RM1-950 ,030302 biochemistry & molecular biology ,Virology ,Molecular biology ,3. Good health ,Internal ribosome entry site ,lcsh:Therapeutics. Pharmacology ,RNAi ,HCV ,Molecular Medicine ,Original Article ,Preclinical imaging - Abstract
We previously identified short synthetic shRNAs (sshRNAs) that target a conserved hepatitis C virus (HCV) sequence within the internal ribosome entry site (IRES) of HCV and potently inhibit HCV IRES-linked gene expression. To assess in vivo liver delivery and activity, the HCV-directed sshRNA SG220 was formulated into lipid nanoparticles (LNP) and injected i.v. into mice whose livers supported stable HCV IRES-luciferase expression from a liver-specific promoter. After a single injection, RNase protection assays for the sshRNA and (3)H labeling of a lipid component of the nanoparticles showed efficient liver uptake of both components and long-lasting survival of a significant fraction of the sshRNA in the liver. In vivo imaging showed a dose-dependent inhibition of luciferase expression (90% 1 day after injection of 2.5 mg/kg sshRNA) with t1/2 for recovery of about 3 weeks. These results demonstrate the ability of moderate levels of i.v.-injected, LNP-formulated sshRNAs to be taken up by liver hepatocytes at a level sufficient to substantially suppress gene expression. Suppression is rapid and durable, suggesting that sshRNAs may have promise as therapeutic agents for liver indications.Molecular Therapy-Nucleic Acids (2013) 2, e123; doi:10.1038/mtna.2013.50; published online 17 September 2013.
- Published
- 2013
- Full Text
- View/download PDF